Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
ARA-290
Overview
A synthetic 11-amino acid peptide derived from the structure of erythropoietin (EPO) that selectively activates the innate repair receptor (IRR), a heteromer of the EPO receptor and the beta common receptor (CD131). Unlike EPO, ARA-290 does not stimulate erythropoiesis or promote thrombosis.
Mechanism of Action
It produces cytoprotective, anti-inflammatory, and tissue-reparative effects by activating the IRR on neurons, immune cells, and endothelial cells.
Research Summary & Key Findings
Phase 2 trials in patients with sarcoidosis-related small fiber neuropathy showed significant improvement in corneal nerve fiber density and reduction in neuropathic pain (Dahan et al., Mol Med, 2013). Preclinical studies demonstrated neuroprotective effects in diabetic neuropathy and cardiac ischemia-reperfusion injury. The selective IRR activation without erythropoietic effects avoids the thrombotic risks that limited EPO-based neuroprotection strategies.
Clinical Status
ARA-290 is currently undergoing clinical trials. It is not yet FDA-approved and is available only through clinical research settings or investigational protocols.
Administration Routes
References
Primary literature
- PubMed: "ARA-290"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "ARA-290"
Registered interventional and observational studies, including status and phase.
- PubChem: "ARA-290"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Pain
Ziconotide (Prialt)
FDA ApprovedA synthetic 25-amino acid peptide identical to omega-conotoxin MVIIA, a neurotoxin found in the venom of the marine cone...
View detailsDifelikefalin (Korsuva)
FDA ApprovedA selective kappa-opioid receptor (KOR) agonist peptide that does not cross the blood-brain barrier, providing periphera...
View detailsPalmitoylethanolamide (PEA)
Research PhaseAn endogenous fatty acid amide belonging to the N-acylethanolamine family, naturally produced by cells in response to ti...
View detailsDynorphin A
Research PhaseDynorphin A is an endogenous opioid peptide of 17 amino acids that preferentially binds to and activates kappa-opioid re...
View detailsNo lawful pathway today
ARA-290 is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so there is nothing for us to sell you here and no consultation to book. That can change: eight peptides moved back to a lawful pathway in February 2026.
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Join the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.